Treatment options for extra-intestinal manifestations of inflammatory bowel disease vary, but remain limited for some

被引：0
作者：
Adis Medical Writers [1 ]
机构：
[1] Adis,
来源：
Drugs & Therapy Perspectives | 2013年 / 29卷 / 6期
关键词：
Inflammatory Bowel Disease; Primary Sclerosing Cholangitis; Inflammatory Bowel Disease Patient; Alemtuzumab; Natalizumab;
D O I：
10.1007/s40267-013-0037-9
中图分类号：
学科分类号：
摘要：
Extra-intestinal manifestations (EIMs) of inflammatory bowel disease can affect many different organ systems. Pharmacological treatment options include corticosteroids, anaesthetics, antiresorptives, immunosuppressants, immunomodulators and biological agents, depending on the individual manifestation. Although for some EIMs, treatment options remain limited to surgery or are not yet clear. Additional research is needed to establish other effective EIM therapies. © 2013 Springer International Publishing Switzerland.
引用
收藏
页码：166 / 170
页数：4
相关论文
共 24 条
  • [1] Trikudanathan G., Venkatesh P.G., Navaneethan U., Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease, Drugs, 72, 18, pp. 2333-2349, (2012)
  • [2] Monsen U., Sorstad J., Hellers G., Et al., Extracolonic diagnoses in ulcerative colitis: An epidemiological study, Am J Gastroenterol, 85, 6, pp. 711-716, (1990)
  • [3] Loftus Jr.E.V., Management of extraintestinal manifestations and other complications of inflammatory bowel disease, Curr Gastroenterol Rep, 6, 6, pp. 506-513, (2004)
  • [4] Talwalkar J.A., Lindor K.D., Primary sclerosing cholangitis, Inflamm Bowel Dis, 11, 1, pp. 62-72, (2005)
  • [5] Loftus Jr.E.V., Harewood G.C., Loftus C.G., Et al., PSC-IBD: A unique form of inflammatory bowel disease associated with primary sclerosing cholangitis, Gut, 54, 1, pp. 91-96, (2005)
  • [6] Navaneethan U., Shen B., Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease, Inflamm Bowel Dis, 16, 9, pp. 1598-1619, (2010)
  • [7] Lichtenstein G.R., Abreu M.T., Cohen R., Et al., American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease, Gastroenterology, 130, 3, pp. 935-939, (2006)
  • [8] Kremer J.M., Alarcon G.S., Lightfoot Jr.R.W., Et al., Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity, Arthritis Rheum, 37, 3, pp. 316-328, (1994)
  • [9] Nathan D.M., Angus P.W., Gibson P.R., Hepatitis B and C virus infections and anti-Tumor necrosis factor-α therapy: Guidelines for clinical approach, J Gastroenterol Hepatol, 21, 9, pp. 1366-1371, (2006)
  • [10] Herfarth H., Obermeier F., Andus T., Et al., Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease, Am J Gastroenterol, 97, 10, pp. 2688-2690, (2002)
123